Blood · 2006 · 76 citations · 48 references
Life SciencesCancer BiologyCell BiologyApoptosisMolecular OncologyApoptosis In CancerApoptosis RegulationApoptotic SignalingArsenic ToxicologyInterferon ResponsesReactive Oxygen SpeciesInhibition Of Interferon ResponsesInterferon ProductionMechanisms Of Arsenic ToxicityOxidative Stress-induced ApoptosisOxidative Stress-induced Cell DeathReactive Oxygen Species GenerationReactive Oxygen Species InjuryReactive Oxygen Species-mediated Cell Death
Adult T-cell leukemia (ATL) is an aggressive lymphoproliferative disease of poor clinical prognosis associated with infection by the human T-cell leukemia virus type I (HTLV-I). The use of arsenic trioxide (As2O3) has been shown to effectively treat acute promyelocytic leukemia (APL) with greater than 80% of patients achieving complete remission. The combination of arsenic and interferon has also shown promising results in the treatment of ATL. The requirement for slow dosage increases of arsenic and the time required to achieve a pharmacologic active dose in patients is a major obstacle because median survival of patients with ATL is about 6 months. In this study we report a potent synergistic effect of the combination of arsenic trioxide and interferon alpha (As/IFN-alpha) with emodin and DHA on cell-cycle arrest and cell death of HTLV-I-infected cells. Importantly, we found that clinically achievable doses of DHA and emodin allowed for reduced arsenic concentrations by 100-fold while still remaining highly toxic to tumor cells. Our data provide a rationale for combined use of As/IFN-alpha with emodin and DHA in patients with ATL refractory to conventional therapy.
48
Mechanisms of action of arsenic trioxide.
Wilson H. Miller, Hyman M. Schipper, Janet Lee et al. · PubMed · 2002 · 956 citations
Medicine, Hematology, Oncology +17